Pike Therapeutics is advancing a proprietary continuous delivery technology aimed at enhancing patient outcomes through a unique transdermal system. This platform is designed to provide a continuous therapeutic effect over a 7-day period, significantly reducing the area under the curve (AUC) and maximum plasma concentration (Cmax) associated with traditional oral drug administration. By minimizing drug exposure, this technology increases tolerability and decreases toxicity, thereby reducing adverse events and side effects. The convenience of a weekly dosing regimen also promotes better patient compliance compared to daily oral multi-dosing, addressing a critical need for patients suffering from chronic conditions like Parkinson's Disease.

Focusing on Parkinson's Disease, Pike Therapeutics is developing transdermal formulations of synthetic CBD and Dronabinol (THC) to target both motor and non-motor symptoms associated with the disease. The company aims to be the first to offer a therapy specifically designed for the management of multiple symptoms in Parkinson's patients, which have historically been inadequately addressed by existing pharmacotherapies. Pike's collaboration with Transdermal Research Pharm Laboratories LLC, which boasts over 70 years of experience in sophisticated delivery systems, further strengthens its development capabilities. Additionally, the potential to utilize an accelerated 505(b)(2) registration pathway may streamline the process of bringing these innovative treatments to market, with implications for addressing other serious neurological diseases in the future.

Canada

Patients need reliable FDA approved cannabinoid treatments. Developing safe and effective cannabinoid formulations with superior drug delivery is our answer.

Pike Therapeutics

Company Details